Since there are currently no highly selective ROS1 inhibitors available (e.g., crizotinib targets ROS1, anaplastic lymphoma kinase (ALK) and mesenchymal epithelial transition factor receptor (MET) kinase), we also investigated whether the observed anti-tumor effects were indeed achieved through ROS1 inhibition. The gene discussed is ALK; the disease is neoplasm.